Trial Watch: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Important context
- Trial eligibility (participation has strict criteria): Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
In plain English
The 30-second version
What happened?
ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Why does it matter?
Phase 4 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
What does this not prove?
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Keep reading for evidence stage, limitations, study details, and sources.
What changed: ClinicalTrials.gov lists Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. (NCT07279935) as a Phase 4 interventional cancer study. The registry status is Recruiting, with the record last updated 2026-08-27.
Study snapshot: Phase 4; Recruiting; planned enrollment 100. Conditions listed: Non-small Cell Lung Cancer. A primary outcome listed by the registry is: To assess the efficacy of osimertinib + chemotherapy by evaluation of PFS in patients who had distant recurrence after adjuvant osimertinib..
This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.
Population / Applicability
Studied in: Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria. (Adults)
Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.
Full evidence details
- Study design
- Not specified in this summary
- Sample size
- 100
- Primary outcome
- To assess the efficacy of osimertinib + chemotherapy by evaluation of PFS in patients who had distant recurrence after adjuvant osimertinib.
- Replication
- Unknown
Funding & Conflicts
ClinicalTrials.gov lists the lead sponsor as AstraZeneca. Sponsorship is reported for transparency and does not establish efficacy.
Regulatory status by jurisdiction
Country or region not specified
- Status
- Investigational
- Last verified
- 2026-08-27
Cancer-type scope for this record is not yet recorded.
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-08-27
Primary evidence supporting this story
- ClinicalTrials.gov — NCT07279935 (opens in a new tab) (Clinical-trial registry) NCT07279935 Primary source NCT07279935
ClinicalTrials.gov — NCT07279935. NCT07279935.
Last reviewed
Trial Watch: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
https://cancerdiscoveries.com/discoveries/trial-watch-osimertinib-combined-with-chemotherapy-in-patients-who-had-distant-recurrence-after-adjuvant-osimertinib-for-egfrm-resectable-sib-iiia-nsclc/
Research type: Registered later-phase trial
What This Means
ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
What This Doesn't Mean
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Why It Matters
Phase 4 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
Important Limitations
- Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
Primary sources
- ClinicalTrials.gov — NCT07279935 — https://clinicaltrials.gov/study/NCT07279935 (NCT07279935)
Date verified: 2026-08-27
Correction status: No correction or retraction